RxDoctor Payments Data

Humaira Abid, MD

Family Medicine · Houston, TXNPI 1326356973

Payments from drug & device makers

$816in general payments, 2019–2025

Across 45 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$152
  • Exact Sciences$103
  • GSK$98
  • Abbott$86
  • Novo Nordisk$63
  • Lilly USA, LLC$47
  • plus $267 from 13 others

What the payments were for

  • Food & beverage$79698%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$816 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,690
Medicare patients
53
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$139,967
JardianceEmpagliflozin94$125,560
RybelsusSemaglutide49$87,391
TrulicityDulaglutide27$48,563
MounjaroTirzepatide25$40,488
LinzessLinaclotide57$39,083
TradjentaLinagliptin31$30,270
JanuviaSitagliptin Phosphate29$28,316
EliquisApixaban34$27,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,055
XareltoRivaroxaban23$18,590
EntrestoSacubitril/Valsartan13$17,020
FarxigaDapagliflozin Propanediol11$13,744
Tresiba Flextouch U-200Insulin Degludec18$11,202
Janumet XrSitagliptin Phos/Metformin Hcl13$11,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$63$227,358164 claims
Lilly USA, LLCTrulicity, Mounjaro$47$89,05152 claims
MerckJanuvia, Janumet Xr$14$39,31842 claims
PfizerEliquis$152$27,72834 claims
GSKTrelegy Ellipta$98$23,05534 claims
Johnson & JohnsonXarelto$15$18,59023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →